Results 71 to 80 of about 843,571 (261)

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study

Frontiers in Pharmacology
BackgroundMultiple myeloma (MM) is a complex hematological malignancy with heterogeneous clinical and pathophysiological backgrounds that influence treatment responses and outcomes.
Rui Bergantim, Rui Bergantim, Rui Bergantim, Rui Bergantim, Sara Peixoto da Silva, Sara Peixoto da Silva, Sara Peixoto da Silva, Vanessa Pinto, Vanessa Pinto, Joana M. Pereira, Joana M. Pereira, Diana Sousa, Diana Sousa, Diana Sousa, Fernanda Trigo, Rune Matthiesen, José E. Guimarães, José E. Guimarães, José E. Guimarães, José E. Guimarães, José E. Guimarães, M. Helena Vasconcelos, M. Helena Vasconcelos, M. Helena Vasconcelos   +23 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy

Biomolecules
Tumor drug resistance, a major cause of treatment failure, involves complex multi-gene networks, remodeling of signaling pathways, and interactions with the tumor microenvironment.
Zhiyan Li, Xiang Jia, Ian Timothy Sembiring Meliala, Yanjun Li, Vivi Kasim   +4 more
doaj   +1 more source

CHANGES IN THE PREVALENCE OF DRUG RESISTANT TUBERCULOSIS

Туберкулез и болезни лёгких, 2017
The tendency of tuberculosis prevalence reduction observed in the Russian Federation is mostly related to the cases without multiple drug resistance (MDR).
V. B. Galkin, S. A. Sterlikov, G. S. Balasanyants, P. K. Yablonsky   +3 more
doaj   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Prevalence of Multiple Antibiotic Resistance Among Salmonella Isolates from Clinical Samples in Dhaka, Bangladesh

Oman Medical Journal
Objectives: Antibiotic resistance in clinical isolates is often correlated to poor disease management or prolonged hospitalization. The study aimed to determine the prevalence of multidrug-resistant (MDR) Salmonella isolates in clinical samples collected
Rashed Imtiaz, Protyaee Saha, Esfat M. Saim Brishty, Sadia Kamal, Manik Chandra Shill, Hasan Mahmud Reza, Preeti Jain   +6 more
doaj   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

The complex relationship between multiple drug resistance and the tumor pH gradient: a review. [PDF]

Cancer Drug Resist, 2022
Koltai T.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

The Drug H⁺ Antiporter FgQdr2 Is Essential for Multiple Drug Resistance, Ion Homeostasis, and Pathogenicity in Fusarium graminearum. [PDF]

J Fungi (Basel), 2022
Ma T, Li Y, Lou Y, Shi J, Sun K, Ma Z, Yan L, Yin Y.   +7 more
europepmc   +1 more source